Cecile Blaustein

Cecile Blaustein is a Vice President of Program Management at Remix Therapeutics. Cecile has over 20 years of experience in the pharmaceutical and biotech industry.

Cecile started their career as a research scientist at Pfizer, where they worked on various drug discovery projects. Cecile then transitioned into project management and took on progressively more senior roles at biotech companies including Disc Medicine Inc., where they were responsible for timelines, budget, contracts and database across programs.

At Disc Medicine, Cecile managed relations with national and international CROs and provided technical/scientific support for hit-to-lead for small molecule discovery program, non-GLP studies for monoclonal antibody program, GLP studies for monoclonal antibody clinical candidate DISC-0974, cell line development campaigns for DISC-0974 and back-up, cGMP manufacturing campaign for DISC-0974, and the submission of Disc’s first preIND. Cecile also helped develop and implement company-wide processes and SOPs with Quality Assurance.

Cecile is an active participant in the hiring of Disc’s R&D team: biology, DMPK, toxicology, CMC, clinical operation and program management. Cecile uses their own network to bring consultants to the team.

Cecile Blaustein has a Ph.D. in Neuroscience from the University Pierre & Marie Curie (Paris VI), a Master of Science (M.S.) in Psychopathology, Development & Neurobehavior from the University Pierre & Marie Curie (Paris VI), and a Master of Science (M.S.) in Psychopharmacology & Addiction from the University Victor Segalen, Bordeaux. Cecile also has a Bachelor of Science (B.S.) in Biochemistry from the University Louis Pasteur, Strasbourg.

Cecile Blaustein works with Josh Powe - Senior Director, Toxicology, Kate O’Brien - Head, Human Resources, and Heather Wasserman - COO & Chief Business Officer. Cecile Blaustein reports to Peter Smith, Co-Founder, & CEO.